vs
Side-by-side financial comparison of Gilead Sciences (GILD) and US Foods Holding Corp. (USFD). Click either name above to swap in a different company.
US Foods Holding Corp. is the larger business by last-quarter revenue ($9.8B vs $7.9B, roughly 1.2× Gilead Sciences). Gilead Sciences runs the higher net margin — 27.5% vs 1.9%, a 25.7% gap on every dollar of revenue. On growth, Gilead Sciences posted the faster year-over-year revenue change (4.7% vs 3.3%). Gilead Sciences produced more free cash flow last quarter ($3.1B vs $159.0M). Over the past eight quarters, Gilead Sciences's revenue compounded faster (8.9% CAGR vs 4.6%).
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
US Foods Holding Corp. is an American food service distributor. It is the second-largest food service distributor in the U.S., after Sysco. The company supplies 250,000 locations including independent restaurants, chain restaurants, healthcare, hospitality, and educational institutions.
GILD vs USFD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.9B | $9.8B |
| Net Profit | $2.2B | $184.0M |
| Gross Margin | 79.5% | 17.6% |
| Operating Margin | 25.0% | 3.3% |
| Net Margin | 27.5% | 1.9% |
| Revenue YoY | 4.7% | 3.3% |
| Net Profit YoY | 22.4% | 178.8% |
| EPS (diluted) | $1.75 | $0.82 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.9B | $9.8B | ||
| Q3 25 | $7.8B | $10.2B | ||
| Q2 25 | $7.1B | $10.1B | ||
| Q1 25 | $6.7B | $9.4B | ||
| Q4 24 | $7.6B | $9.5B | ||
| Q3 24 | $7.5B | $9.7B | ||
| Q2 24 | $7.0B | $9.7B | ||
| Q1 24 | $6.7B | $8.9B |
| Q4 25 | $2.2B | $184.0M | ||
| Q3 25 | $3.1B | $153.0M | ||
| Q2 25 | $2.0B | $224.0M | ||
| Q1 25 | $1.3B | $115.0M | ||
| Q4 24 | $1.8B | $66.0M | ||
| Q3 24 | $1.3B | $148.0M | ||
| Q2 24 | $1.6B | $198.0M | ||
| Q1 24 | $-4.2B | $82.0M |
| Q4 25 | 79.5% | 17.6% | ||
| Q3 25 | 79.8% | 17.2% | ||
| Q2 25 | 78.8% | 17.6% | ||
| Q1 25 | 76.9% | 17.3% | ||
| Q4 24 | 79.1% | 17.6% | ||
| Q3 24 | 79.1% | 17.1% | ||
| Q2 24 | 77.8% | 17.6% | ||
| Q1 24 | 76.8% | 16.7% |
| Q4 25 | 25.0% | 3.3% | ||
| Q3 25 | 42.8% | 2.8% | ||
| Q2 25 | 34.9% | 3.7% | ||
| Q1 25 | 33.6% | 2.4% | ||
| Q4 24 | 32.4% | 3.2% | ||
| Q3 24 | 11.8% | 2.9% | ||
| Q2 24 | 38.0% | 3.6% | ||
| Q1 24 | -64.6% | 1.8% |
| Q4 25 | 27.5% | 1.9% | ||
| Q3 25 | 39.3% | 1.5% | ||
| Q2 25 | 27.7% | 2.2% | ||
| Q1 25 | 19.7% | 1.2% | ||
| Q4 24 | 23.6% | 0.7% | ||
| Q3 24 | 16.6% | 1.5% | ||
| Q2 24 | 23.2% | 2.0% | ||
| Q1 24 | -62.4% | 0.9% |
| Q4 25 | $1.75 | $0.82 | ||
| Q3 25 | $2.43 | $0.67 | ||
| Q2 25 | $1.56 | $0.96 | ||
| Q1 25 | $1.04 | $0.49 | ||
| Q4 24 | $1.43 | $0.28 | ||
| Q3 24 | $1.00 | $0.61 | ||
| Q2 24 | $1.29 | $0.80 | ||
| Q1 24 | $-3.34 | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $68.0M | $41.0M |
| Total DebtLower is stronger | $24.9B | $5.1B |
| Stockholders' EquityBook value | $22.7B | $4.3B |
| Total Assets | $59.0B | $13.9B |
| Debt / EquityLower = less leverage | 1.10× | 1.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.0M | $41.0M | ||
| Q3 25 | $19.0M | $56.0M | ||
| Q2 25 | $69.0M | $61.0M | ||
| Q1 25 | — | $101.0M | ||
| Q4 24 | — | $59.0M | ||
| Q3 24 | — | $81.0M | ||
| Q2 24 | — | $405.0M | ||
| Q1 24 | — | $267.0M |
| Q4 25 | $24.9B | $5.1B | ||
| Q3 25 | $24.9B | $4.8B | ||
| Q2 25 | $24.9B | $4.7B | ||
| Q1 25 | $25.0B | $4.7B | ||
| Q4 24 | $26.7B | $4.8B | ||
| Q3 24 | $23.2B | $4.7B | ||
| Q2 24 | $23.3B | $4.6B | ||
| Q1 24 | $25.2B | $4.6B |
| Q4 25 | $22.7B | $4.3B | ||
| Q3 25 | $21.5B | $4.5B | ||
| Q2 25 | $19.7B | $4.6B | ||
| Q1 25 | $19.2B | $4.6B | ||
| Q4 24 | $19.3B | $4.5B | ||
| Q3 24 | $18.5B | $4.6B | ||
| Q2 24 | $18.3B | $5.0B | ||
| Q1 24 | $17.5B | $4.8B |
| Q4 25 | $59.0B | $13.9B | ||
| Q3 25 | $58.5B | $14.0B | ||
| Q2 25 | $55.7B | $13.8B | ||
| Q1 25 | $56.4B | $13.7B | ||
| Q4 24 | $59.0B | $13.4B | ||
| Q3 24 | $54.5B | $13.5B | ||
| Q2 24 | $53.6B | $13.7B | ||
| Q1 24 | $56.3B | $13.4B |
| Q4 25 | 1.10× | 1.18× | ||
| Q3 25 | 1.16× | 1.08× | ||
| Q2 25 | 1.27× | 1.02× | ||
| Q1 25 | 1.30× | 1.02× | ||
| Q4 24 | 1.38× | 1.06× | ||
| Q3 24 | 1.26× | 1.01× | ||
| Q2 24 | 1.28× | 0.92× | ||
| Q1 24 | 1.44× | 0.95× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.3B | $293.0M |
| Free Cash FlowOCF − Capex | $3.1B | $159.0M |
| FCF MarginFCF / Revenue | 39.4% | 1.6% |
| Capex IntensityCapex / Revenue | 2.6% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.52× | 1.59× |
| TTM Free Cash FlowTrailing 4 quarters | $9.5B | $959.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.3B | $293.0M | ||
| Q3 25 | $4.1B | $351.0M | ||
| Q2 25 | $827.0M | $334.0M | ||
| Q1 25 | $1.8B | $391.0M | ||
| Q4 24 | $3.0B | $283.0M | ||
| Q3 24 | $4.3B | $270.0M | ||
| Q2 24 | $1.3B | $482.0M | ||
| Q1 24 | $2.2B | $139.0M |
| Q4 25 | $3.1B | $159.0M | ||
| Q3 25 | $4.0B | $236.0M | ||
| Q2 25 | $720.0M | $257.0M | ||
| Q1 25 | $1.7B | $307.0M | ||
| Q4 24 | $2.8B | $178.0M | ||
| Q3 24 | $4.2B | $190.0M | ||
| Q2 24 | $1.2B | $413.0M | ||
| Q1 24 | $2.1B | $52.0M |
| Q4 25 | 39.4% | 1.6% | ||
| Q3 25 | 51.0% | 2.3% | ||
| Q2 25 | 10.2% | 2.5% | ||
| Q1 25 | 24.8% | 3.3% | ||
| Q4 24 | 37.4% | 1.9% | ||
| Q3 24 | 55.2% | 2.0% | ||
| Q2 24 | 17.2% | 4.3% | ||
| Q1 24 | 31.6% | 0.6% |
| Q4 25 | 2.6% | 1.4% | ||
| Q3 25 | 1.9% | 1.1% | ||
| Q2 25 | 1.5% | 0.8% | ||
| Q1 25 | 1.6% | 0.9% | ||
| Q4 24 | 1.9% | 1.1% | ||
| Q3 24 | 1.9% | 0.8% | ||
| Q2 24 | 1.9% | 0.7% | ||
| Q1 24 | 1.6% | 1.0% |
| Q4 25 | 1.52× | 1.59× | ||
| Q3 25 | 1.35× | 2.29× | ||
| Q2 25 | 0.42× | 1.49× | ||
| Q1 25 | 1.34× | 3.40× | ||
| Q4 24 | 1.67× | 4.29× | ||
| Q3 24 | 3.44× | 1.82× | ||
| Q2 24 | 0.82× | 2.43× | ||
| Q1 24 | — | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
USFD
| Product One | $3.5B | 36% |
| Product Two | $1.7B | 17% |
| Product Three | $1.7B | 17% |
| Product Four | $985.0M | 10% |
| Product Five | $901.0M | 9% |
| Product Six | $580.0M | 6% |
| Product Seven | $485.0M | 5% |
